← Back to Search

Magnetic Resonance Elastography for Liver Cancer

N/A

Recruiting

Led By Priya Bhosale

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Liver cancer

Available tumor and liver parenchyma tissue (biopsy-proven HCC)

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 18 months

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing how well an investigational scan works with standard imaging to detect response to treatment in patients with liver cancer.

Who is the study for?

This trial is for patients with advanced liver cancer that has spread, who have biopsy-proven hepatocellular carcinoma (HCC) and can provide tissue samples. Participants must not have any conditions that make MRI unsafe, like metal implants or fragments in the body, and cannot be pregnant. They must also be able to give informed consent.

What is being tested?

The study is testing a new type of scan called Magnetic Resonance Elastography (MRE), alongside standard MRI scans, to see if they can better detect how well treatments are working in patients with advanced liver cancer.

What are the potential side effects?

Since MRE and MRI are imaging techniques rather than drugs or surgeries, side effects are minimal but may include discomfort from lying still during the procedure or anxiety in confined spaces (claustrophobia).

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have liver cancer.

Select...

I have biopsy-proven liver cancer tissue available for testing.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 18 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~18 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and 18 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Change in magnetic resonance elastography (MRE) liver tumor stiffness

Change in percent non-viable/necrotic tumor

Secondary study objectives

Change in tumor size and enhancement

Overall survival

Time to tumor progression

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Diagnostic (MRI/MRE)Experimental Treatment2 Interventions

Patients undergo standard of care MRI and MRE over 30-90 minutes within 5 days of liver biopsy before receiving any medical treatment for HCC, at 6 weeks after medical treatment for HCC, and then every 12 weeks for up to 24 months.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Magnetic Resonance Imaging

2017

Completed Phase 3

~1160

0 / 2Eligibility criteria met